Skip to main content

Table 3 Univariate and multivariate analyses of disease-free survival in patients with hormone receptor-positive/HER2-negative primary breast cancer

From: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

  

Univariate

Multivariate

  

Total (n=142)

Hazard ratio

(95% CI)

P-value

Hazard ratio

(95% CI)

P-value

Ki67-p53

Low Ki67 LI and Negative p53

88

1

  

1

  
 

High Ki67 LI and/or Positive p53

54

9.3

3.5-24.5

< 0.0001

11.6

4.2-32.3

< 0.0001

FOXA1

Low

20

1

     
 

High

119

1.4

0.51-3.6

0.54

   

GATA3

Negative

30

1

     
 

Positive

112

1.5

0.65-3.5

0.34

   

Basal phenotype marker

Negative

9

1

     

(CK5/6, CK14, EGFR)

Positive

133

1.0

0.24-4.3

0.98

   

P-cadherin

Low

90

1

     
 

High

52

1.3

0.59-2.8

0.52

   

Tumor size

<5.0 cm

17

1

  

1

  
 

5.0 cm

122

4.9

2.1-11.4

0.0003

5.7

2.3-14.1

0.0002

Lymph-node metastasis

(−)

80

1

     
 

(+)

59

3.8

1.6-8.8

0.0020

   

Nuclear grade

1, 2

111

1

     
 

3

31

4.2

1.9-9.0

0.0002

   

Chemotherapy

No

93

1

  

1

  
 

Yes

49

2.6

1.2-5.7

0.014

3.5

1.5-7.9

0.0028

  1. Abbreviation: 95%CI 95% confidence interval, LI labeling index.